A recent retrospective cohort study conducted in Japan has shed light on the comparative safety of mirogabalin and pregabalin in treating neuropathic pain among older adults. The research aimed to determine whether mirogabalin is associated with fewer serious adverse events, particularly fall-related fractures, than its counterpart pregabalin.
Methodology and Patient Demographics
Utilizing the DeSC database, the study analyzed data from 130,244 patients aged 65 and above who were prescribed either mirogabalin or pregabalin between April 2019 and May 2021. The primary outcomes focused on the incidence of fractures and the necessity to switch medications. Statistical methods, including Kaplan-Meier curves and multivariable Cox proportional hazards models, were employed to compare the two drug groups. A sensitivity analysis further examined patients who initiated treatment without concurrent analgesic medications.
Comparative Outcomes and Risk Assessment
During a median follow-up period of 2.8 months, 22.8% of patients received mirogabalin, while 77.2% were on pregabalin. The incidence rates of the primary outcomes were 50.1 per 100 person-years for the mirogabalin group and 42.8 per 100 person-years for the pregabalin group. The Cox regression analysis indicated that mirogabalin users experienced a slightly reduced risk of adverse outcomes, with a hazard ratio of 0.93. However, the sensitivity analysis revealed no significant difference when excluding patients on other analgesic medications.
Key Inferences:
- Mirogabalin may offer a marginally lower risk of fractures compared to pregabalin in the elderly.
- The clinical significance of the reduced risk appears minimal based on current data.
- Concurrent use of other analgesics does not significantly influence the comparative outcomes between the two drugs.
The findings suggest a potential advantage of mirogabalin over pregabalin in minimizing adverse events among older patients. However, the difference observed does not reach clinical significance, indicating that both medications perform similarly in real-world settings. Further research with extended follow-up periods and broader patient populations is necessary to substantiate these preliminary results.
Encouragingly, the study provides valuable insights into the safety profiles of mirogabalin and pregabalin, aiding healthcare professionals in making informed decisions tailored to the needs of elderly patients suffering from neuropathic pain. Clinicians should consider the marginal benefits of mirogabalin alongside other factors such as patient tolerance, cost, and overall health status when prescribing these medications.
Ultimately, while mirogabalin shows promise in reducing the risk of fall-related fractures, its benefits over pregabalin remain modest. Ongoing surveillance and additional studies are essential to fully understand the long-term implications of using mirogabalin in the geriatric population, ensuring optimal pain management with minimal adverse effects.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
